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Abstract
Introduction Arginine vasopressin (AVP) is increasingly used to
treat sepsis-related vasodilation and to decrease catecholamine
requirements. However, AVP infusion may be associated with a
marked decrease in systemic blood flow and oxygen transport.
The purpose of the present study was to evaluate whether
dobutamine may be titrated to reverse the AVP-related decrease
in cardiac index (CI) and systemic oxygen delivery index (DO2I)
in an established model of ovine endotoxemia.
Methods Twenty-four adult ewes were chronically instrumented
to determine cardiopulmonary hemodynamics and global
oxygen transport. All ewes received a continuous endotoxin
infusion that contributed to a hypotensive-hyperdynamic
circulation and death of five sheep. After 16 hours of
endotoxemia, the surviving ewes (n = 19; weight 35.6 ± 1.5 kg
(mean ± SEM)) were randomized to receive either AVP (0.04
Umin-1) and dobutamine (n = 8) or the vehicle (normal saline; n
= 6) and compared with a third group treated with AVP infusion
alone (n = 5). Dobutamine infusion was started at an initial rate
of 2 μg kg-1min-1 and was increased to 5 and 10 μg kg-1 min-1
after 30 and 60 minutes, respectively.
Results AVP infusion increased mean arterial pressure (MAP)
and systemic vascular resistance index at the expense of a
markedly decreased CI (4.1 ± 0.5 versus 8.2 ± 0.3 l min-1 m-2),
DO2I (577 ± 68 versus 1,150 ± 50 ml min-1 m-2) and mixed-
venous oxygen saturation (SvO2; 54.5 ± 1.8% versus 69.4 ±
1.0%; all p  < 0.001 versus control). Dobutamine dose-
dependently reversed the decrease in CI (8.8 ± 0.7 l min-1 m-2
versus 4.4 ± 0.5 l min-1 m-2), DO2I (1323 ± 102 versus 633 ±
61 ml min-1 m-2) and SvO2 (72.2 ± 1.7% versus 56.5 ± 2.0%, all
p < 0.001 at dobutamine 10 μg kg-1 min-1 versus AVP group)
and further increased MAP.
Conclusion This study provides evidence that dobutamine is a
useful agent for reversing the AVP-associated impairment in
systemic blood flow and global oxygen transport.
Introduction
Septic shock is the most common cause of death in non-cor-
onary intensive care units [1] mainly as a result of catecho-
lamine-refractory arterial hypotension and multiple organ
failure. Arginine vasopressin (AVP) is emerging as a promising
adjunct in the treatment of catecholamine-refractory septic
shock. In this regard, AVP may be administered either as endo-
crine support targeting to (re)establish adequate AVP plasma
levels [2] or as a vasopressor agent seeking to increase mean
arterial pressure (MAP) [3]. However, the exact values for 'ade-
quate' AVP plasma levels in endocrine support have not yet
been defined.
AVP = arginine vasopressin; CI = cardiac index; DO2I = oxygen delivery index; HR = heart rate; LVSWI = left ventricular stroke work index; MAP = 
mean arterial pressure; MPAP = mean pulmonary arterial pressure; O2-ER = oxygen extraction rate; PAOP = pulmonary arterial occlusion pressure; 
PVRI = pulmonary vascular resistance index; RVSWI = right ventricular stroke work index; SvO2 = mixed-venous oxygen saturation; SVRI = systemic 
vascular resistance index; VO2I = oxygen consumption index.Critical Care    Vol 10 No 5    Ertmer et al.
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The hemodynamic state of patients with septic shock treated
with aggressive volume challenge is usually characterized by a
hyperdynamic circulation, as indicated by increases in cardiac
index (CI) and heart rate (HR) and decreases in MAP and sys-
temic vascular resistance index (SVRI). As tissue oxygen
requirements are typically increased in patients with septic
shock, one of the principal treatment strategies is to maintain
high cardiac output and a balanced oxygen supply–demand
relationship [4,5]. In contrast, establishing supranormal oxy-
gen delivery has shown inconsistent results and is thus not
recommended by the current sepsis guidelines [6,7].
Especially when used in higher doses, AVP may decrease sys-
temic and regional blood flow, thereby impairing tissue oxygen
supply [3,8-10]. The latter condition may potentially increase
the risk for a so-called 'oxygen supply dependency' and foster
the pathogenesis of organ failure or even death. Given that
AVP decreases systemic oxygen delivery index (DO2I), it
seems rational to combine AVP with an inotropic agent that is
able to reverse the decrease in CI and DO2I.
Whereas some inotropic drugs, such as dopexamine and mil-
rinone, consistently decrease MAP and therefore carry the risk
of further decreasing organ perfusion in septic shock [11,12],
dobutamine either increases MAP or leaves it unchanged in
normovolemic subjects [13].
We hypothesized that dobutamine is a useful agent for
decreasing the AVP-associated decreases in systemic blood
flow and global oxygen transport in ovine endotoxemia. The
present study was conducted to evaluate whether titrated
dobutamine is suitable to reverse decreases in CI, DO2I and
mixed-venous oxygen saturation (SvO2) resulting from sole
AVP infusion in unanesthetized endotoxemic sheep.
Materials and methods
After study approval by the Local Animal Research Committee,
24 adult ewes were chronically instrumented to determine car-
diopulmonary hemodynamics and global oxygen transport with
the use of an established protocol [8,11,14-16].
Animal preparation
Induction of anesthesia was performed by intramuscular injec-
tion of S-ketamine (Ketanest 50, 10 mg kg-1; Parke-Davis, Ber-
lin, Freiburg, Germany) and xylazine 2% (Xylazin, 0.15 mg kg-
1; CEVA Tiergesundheit GmbH, Düsseldorf, Germany). There-
after, anesthesia was maintained with a continuous intrave-
nous infusion of propofol (Disoprivan, 4 to 6 mg kg-1 h-1;
AstraZeneca, Schwetzigen, Germany). The unconscious,
spontaneously breathing ewes were instrumented with an ind-
welling pulmonary artery catheter, which was inserted by
means of the right jugular vein through an introducer sheath
(8.5 Fr. Catheter Introducer Set; pvb Medizintechnik GmbH,
Kirchseeon, Germany; 7.5 Fr. Edwards Swan Ganz; Edwards
Critical Care Division, Irvine, CA, USA) and a left femoral arte-
rial catheter (18-gauge Leader Catheter; Vygon, Aachen, Ger-
many). In addition, a Foley catheter (Porgès S.A., Le Plessis
Robinson-Cedex, France) was placed into the urinary bladder
to monitor urine output. Intravenous Ceftriaxone (Rocephin 1
g; Hoffmann-La Roche AG, Grenzach-Wyhlen, Germany) was
administered as post-surgical infection prophylaxis.
Instrumentation was followed by a 24 hour period of recovery.
To prevent postoperative dehydration, all sheep received a
continuous intravenous infusion of lactated Ringer's solution
(2 ml kg-1 h-1).
Measurement equipment and determined variables
Intravascular catheters were connected to a physiological
recorder (Hellige Servomed; Hellige, Freiburg, Germany) by
means of pressure transducers (DTX pressure transducer;
Ohmeda, Erlangen, Germany). Hemodynamic monitoring
included MAP, mean pulmonary arterial pressure (MPAP),
central venous pressure, and pulmonary artery occlusion pres-
sure (PAOP). HR was determined by calculating the mean fre-
quency of arterial pressure curve peaks. Core body
temperature (T) was continuously measured by the thermistor
positioned at the tip of the pulmonary artery catheter. The ther-
modilution technique (9520A cardiac output computer;
Edward Lifescience, Irvine, CA, USA) was applied to measure
cardiac output by threefold central venous injection of 10 ml of
physiological saline solution at a temperature of 2 to 5°C. CI,
SVRI, pulmonary vascular resistance index (PVRI), stroke vol-
ume index, and left and right ventricular stroke work indices
(LVSWI and RVSWI, respectively) were determined with
standard equations [11].
Arterial and mixed venous blood samples (0.5 ml each) were
collected in heparinized tubes designed for the determination
of blood gases (Sarstedt, Nümbrecht, Germany). Partial pres-
sures of O2 and CO2 (pO2 and pCO2, respectively) as well as
pH were determined with an ABL 725 blood gas analyzer with
SAT 100 calibration (Radiometer Copenhagen, Copenhagen,
Denmark). In addition, hemoglobin concentration, arterial oxy-
gen saturation (SaO2), SvO2, and arterial lactate concentra-
tions were assessed. Standard bicarbonate (HCO3 
-) and
base excess (BE) were calculated from pCO2 and pH. DO2I,
oxygen consumption index (VO2I) and oxygen extraction rate
(O2-ER) were determined with standard formulae [11]. All
measurements were performed in accordance with the exper-
imental protocol.
Experimental protocol
Inclusion criteria for the present study were an initial HR of less
than 100 beats min-1, a core body temperature of 39.8°C or
less, a MPAP of less than 25 mmHg and an arterial lactate
concentration of one mmol l-1 or less.
During the experimental protocol, all ewes were breathing
spontaneously and were studied in a conscious state. AnimalsAvailable online http://ccforum.com/content/10/5/R144
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were housed in metabolic cages with free access to water and
food.
After obtaining baseline cardiopulmonary and oxygen trans-
port data (T1), a hypotensive–hyperdynamic circulation was
induced and maintained by a continuous infusion of Salmo-
nella typhosa endotoxin (10 ng kg-1 min-1; Sigma Chemicals,
Deisenhofen, Germany) for the next 18.5 hours. At the same
time as endotoxin infusion was started, lactated Ringer's solu-
tion was increased from 2 to 4 ml kg-1 h-1. Previous studies had
demonstrated that this approach keeps PAOP, central venous
pressure (CVP) and stroke volume index (SVI) at baseline and
guarantees normovolemia of the animals [15]. During the first
14 hours of endotoxemia, five sheep died as a result of right
heart failure and were excluded from the study. In the surviving
animals (n = 19), cardiopulmonary and oxygen transport data
were determined after 16 hours of a continuous endotoxin
infusion (T2). Thereafter, sheep were randomly allocated to
either receive AVP and dobutamine (AVP-Dobu group; n = 8)
or the vehicle (control group; n = 6) and compared with a third
group treated with AVP infusion alone (AVP group; n = 5). The
AVP and AVP-Dobu group received a continuous AVP infusion
(Pitressin™ 0.04 U min-1; Parke Davis Ltd, Berlin, Freiburg,
Germany). After one hour, dobutamine (Dobutamin Liquid Fre-
senius; Fresenius Kabi, Bad Homburg, Germany) was simulta-
neously administered at incremental doses in the AVP-Dobu
group. Dobutamine infusion was started at a rate of 2 μg kg-1
min-1 and increased to 5 and 10 μg kg-1 min-1 after 30 and 60
minutes, respectively. The control group received only the
vehicle (normal saline). Hemodynamic variables and oxygen
transport data were analyzed after one hour of AVP infusion
(T3), as well as 30 minutes after each dose of dobutamine (T4
to T6). Measurements in the control and AVP group were
made at the corresponding time points.
At the end of the experiment the surviving ewes were deeply
anesthetized with propofol (4 mg kg-1) and killed with a lethal
dose of 100 ml potassium chloride solution (7.45%).
Statistical analysis
Data are expressed as means ± SEM. Sigma Stat 3.10 soft-
ware (SPSS, Chicago, IL, USA) was used for statistical analy-
sis. After confirming normal distribution of all variables
(Kolmogorov–Smirnov test), differences within and between
groups were analyzed with a two-way analysis of variance
(ANOVA) for repeated measurements. After confirming signif-
icant group differences over time, appropriate post hoc com-
parisons (Student–Newman–Keuls) were performed. For all
statistical tests, an error probability of p < 0.05 was regarded
as statistically significant.
Results
The entire experiment was performed in 19 sheep with an
average weight of 35.6 ± 1.5 kg. Hemodynamic and global
oxygen transport variables before endotoxin infusion (T1) are
presented in Figures 1 and 2 and Tables 1, 2, 3. There were
no statistical differences between groups at randomization.
In all groups, hemoglobin concentration, CVP and PAOP
remained constant throughout the entire experiment (Tables 1
and 3).
Effects of endotoxin infusion
Endotoxin infusion contributed to a hypotensive–hyperdy-
namic circulation characterized by decreases in MAP (p =
0.012 versus healthy state, T1) and SVRI (p = 0.02 versus
healthy state, T1) as well as increases in HR and CI (each p <
0.001 versus healthy state, T1; Figure 1). In comparison with
healthy sheep, LVSWI was significantly decreased after 16
hours of endotoxemia (p = 0.032; Table 1).
All endotoxemic ewes suffered from pulmonary hypertension,
as indicated by increases in MPAP (p < 0.001) and PVRI (p =
0.042) as compared with the healthy state (T1; Table 1).
In addition, endotoxin infusion contributed to increases in
DO2I (p = 0.003) and SvO2 (p = 0.04) that were accompanied
by a decrease in O2-ER (p = 0.026; all versus healthy state,
T1; Figure 2).
In comparison with the healthy state, arterial lactate concentra-
tion and core body temperature were elevated (p < 0.001)
without affecting acid–base balance (Table 2). Urinary output
was not significantly altered by endotoxin infusion but tended
to increase (Table 3).
There were no statistical differences between groups at T2.
Effects of AVP infusion in the AVP group
AVP infusion reversed the endotoxin-associated hypotensive–
hyperdynamic circulation, as indicated by a decrease in HR
and CI and an increase in MAP and SVRI (each p < 0.001 ver-
sus control; Figure 1).
Infusion of AVP resulted in a further increase in PVRI (p =
0.046 versus control) that was associated with a significant
decrease in RVSWI (p = 0.047 versus control; Table 1).
In addition, AVP infusion led to a marked decrease in DO2I,
which was accompanied by a sustained increase in O2-ER
and a decrease in SvO2 (each p < 0.001 versus control; Figure
2). In this study, AVP had no significant impact on VO2I but
tended to decrease it. Acid–base variables remained constant
(Table 2).
Urinary output was markedly increased by AVP infusion (p <
0.001 versus control; Table 3).
There was no difference between the AVP and AVP-Dobu
group at the time of AVP infusion alone (T3).Critical Care    Vol 10 No 5    Ertmer et al.
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Effects of dobutamine infusion
Dobutamine increased MAP (p = 0.009), CI (p < 0.001), HR
(p < 0.001), and LVSWI (p = 0.018) and decreased SVRI (p
< 0.001; all AVP-Dobu versus AVP group at dobutamine 10
μg kg-1 min-1; T6) in a dose-dependent manner (Figure 1). In
addition, the AVP-associated increase in PVRI was attenuated
by dobutamine (p = 0.064; AVP-Dobu versus AVP group at
dobutamine 10 μg kg-1 min-1; T6; Table 1).
Whereas O2-ER was markedly decreased after dobutamine
infusion, DO2I and SvO2 were significantly increased (each p
< 0.001; AVP-Dobu versus AVP group at dobutamine 10 μg
kg-1 min-1; T6; Figure 2). Dobutamine had no effect on VO2I
and acid–base balance. Similarly, urinary output did not
change in comparison with the AVP group (Table 3).
Dobutamine-related effects were dose-dependent and most
pronounced at the highest dosage (namely 10 μg kg-1 min-1;
T6).
Discussion
In the present study the effects of a titrated dobutamine infu-
sion on cardiopulmonary hemodynamics and global oxygen
transport were evaluated in endotoxemic sheep treated with a
fixed AVP infusion (0.04 U min-1). The major finding is that dob-
utamine reversed the AVP-associated impairment in CI, DO2I
and SvO2 in a dose-dependent manner.
To our knowledge, this is the first study elucidating the inter-
actions between AVP and titrated dobutamine in awake ani-
mals suffering from chronic endotoxemia. Martikainen and
Figure 1
Changes in mean arterial pressure (MAP), systemic vascular resistance index (SVRI), heart rate (HR) and cardiac index (CI) Changes in mean arterial pressure (MAP), systemic vascular resistance index (SVRI), heart rate (HR) and cardiac index (CI). AVP, arginine vaso-
pressin; AVP-Dobu, group treated with AVP and dobutamine; T1, healthy baseline; T2, endotoxemic baseline; T3, AVP or placebo; T4, T5, T6, AVP 
+ dobutamine 2, 5 and 10 μg kg-1·min-1 or placebo, respectively. *p < 0.05 versus control, ***p < 0.001 versus control, †p < 0.05 versus AVP, ††p < 
0.01 versus AVP, †††p < 0.001 versus AVP, ‡‡‡p < 0.001 versus T1, §p < 0.05 versus T4, §§p < 0.01 versus T4, §§§p < 0.001 versus T4, ||p < 0.05 
versus T5, ||||||p < 0.001 versus T5.Available online http://ccforum.com/content/10/5/R144
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colleagues have already reported that dobutamine compen-
sates for deleterious hemodynamic and metabolic effects of
AVP in the splanchnic region in endotoxic shock in anesthe-
tized, continuously ventilated domestic pigs [17]. However, it
is noteworthy that the latter authors used almost twice the
dosage of AVP (0.002 U kg-1 min-1) than we did in the present
study (about 0.001 U kg-1 min-1). Whereas only low-dose dob-
utamine (2.8 μg kg-1 min-1) was infused in the experiment by
Martikainen and colleagues [17], the present study investi-
gated the effects of different doses.
Notably, we used a large animal model that closely reflects
hemodynamic changes seen in septic patients with a hyperdy-
namic circulation [18,19]. In harmony with previous studies
using the same or similar sepsis models [8,11,14-16,20],
endotoxin infusion was linked to a decrease in vascular resist-
ance and MAP as well as an increase in CI, and was accom-
panied by elevations in core body temperature and arterial
lactate concentrations.
In the present study, AVP was used in a moderate dosage
(0.04 U min-1), seeking to reverse endotoxin-induced vasodila-
tion and arterial hypotension. In accordance with previous
studies, AVP infusion was linked to substantial vasoconstric-
tion, as reflected by a significant increase in SVRI [8,15]. The
mechanisms of this finding include, but may not be restricted
to, activation of vascular V1 receptors [21], inhibition of NO-
mediated cyclic GMP production [22] and inhibition of vascu-
lar ATP-controlled potassium channels (KATP channels) [23].
The AVP-induced decrease in HR may be explained by barore-
ceptor activation and is in line with previous experimental and
clinical studies [8,21,24]. The subsequent decrease in CI was
associated with a proportional decrease in DO2I. To maintain
VO2I above critical threshold values, O2-ER had to be
increased. Nevertheless, VO2I tended to decrease in the AVP-
treated groups.
In this context, it should be kept in mind that a marked
decrease in DO2I carries the risk for impaired regional oxygen
supply, especially of the gastrointestinal tract. As a result of
increased mucosal oxygen consumption in patients with sep-
sis [25], a decrease in oxygen delivery may impair the gut
mucosal barrier, thereby leading to bacterial translocation and
fostering the inflammatory septic cascade [26]. Strategies to
prevent an AVP-associated impairment in DO2I therefore
seem to be of significant clinical relevance.
Dobutamine is a partial agonist on β1- and β2-adrenoceptors
with little effect on α-adrenoceptors, and increases HR, CI and
DO2I within a therapeutic range of 1 to 20 μg kg-1 min-1. In nor-
movolemic subjects the increase in CI is associated with no
change or an increase in systemic blood pressure. In contrast,
in the presence of hypovolemia, dobutamine may increase
myocardial oxygen demand and decrease MAP [13]. In the
Figure 2
Changes in oxygen delivery index (DO2I), oxygen extraction rate (O2- ER) and mixed-venous oxygen saturation (SvO2) Changes in oxygen delivery index (DO2I), oxygen extraction rate (O2-
ER) and mixed-venous oxygen saturation (SvO2). AVP, arginine vaso-
pressin; AVP-Dobu, group treated with AVP and dobutamine; T1 = 
healthy baseline, T2 = endotoxemic baseline, T3 = AVP or placebo, T4, 
T5, T6 = AVP + dobutamine 2, 5 and 10 μg.kg-1·min-1 or placebo, 
respectively, *p < 0.05 versus control, **p < 0.01 versus control, ***p < 
0.001 versus control, †p < 0.05 versus AVP, ††p < 0.01 versus AVP, 
†††p < 0.001 versus AVP, ‡p < 0.05 versus T1, ‡‡p < 0.01 versus T1, 
§§p < 0.01 versus T4, §§§p < 0.001 versus T4, ||||p < 0.01 versus T5, 
||||||p < 0.001 versus T5.Critical Care    Vol 10 No 5    Ertmer et al.
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present study, dobutamine caused dose-dependent increases
in MAP, CI, HR, DO2I and SvO2, thereby improving both sys-
temic hemodynamics and global oxygen transport. Our group
previously reported that dopexamine, a synthetic catecho-
lamine with intrinsic activity on dopaminergic DA1 and DA2
receptors as well as on β1- and β2-adrenoceptors, increases
HR, CI and LVSWI in AVP-treated endotoxemic sheep [11].
However, probably because of the vasodilating action through
vascular DA1- and β2-receptors, dopexamine decreased MAP,
thereby limiting its therapeutic use.
Dobutamine is currently the inotropic agent of choice to
increase CI in patients with septic shock with an inappropri-
ately low cardiac output [7,27]. The present study provides
evidence that dobutamine may also be suitable for reversing
the AVP-related impairment in CI, DO2I and SvO2. In addition,
dobutamine decreased SVRI to values noticed before injury
and improved LVSWI, a marker of myocardial contractility.
However, it must be considered that dobutamine increased
HR to values noticed before AVP infusion and may therefore
potentially bear the risk of adverse cardiac events, such as
tachyarrhythmias and myocardial ischemia [28]. Although the
AVP-associated decreases in HR, CI and DO2I seem critical,
no clinical study has yet shown an impaired outcome due to
these AVP-related side effects. Conversely, no study has ever
shown benefit from elevating HR, CI and DO2I in AVP-treated
patients. Nevertheless, it is noteworthy that an early goal-
directed therapy seeking to establish a SvO2 of more than
70% has proven to decrease mortality in patients with septic
shock [29].
The present study has some limitations that we acknowledge.
First, we used an animal model to mimic hemodynamics in
human sepsis. In harmony with previous studies of our group,
endotoxemic sheep suffered from moderate arterial hypoten-
sion (MAP 82 ± 2 mmHg) [8,11,14-16]. In this context, how-
ever, it is important that sheep are physiologically
characterized by higher blood pressures than humans. A
Table 1
Changes in hemodynamic variables in endotoxemic sheep.
Variable Group T1 T2 T3 T4 T5 T6
MPAP (mmHg) Control 18 ± 1 25 ± 1‡‡‡ 26 ± 1 26 ± 1 26 ± 1 25 ± 1
AVP 19 ± 1 27 ± 1‡‡‡ 27 ± 2 27 ± 2 26 ± 2 27 ± 3
AVP-Dobu 20 ± 1 25 ± 1‡‡‡ 25 ± 1 25 ± 1 25 ± 1 24 ± 1
PVRI (dyne.s.cm-5·m2) Control 99 ± 8 138 ± 18‡ 142 ± 14 145 ± 13 146 ± 11 140 ± 10
AVP 98 ± 12 124 ± 18 184 ± 34* 173 ± 37 179 ± 35 176 ± 35
AVP-Dobu 107 ± 9 125 ± 12 191 ± 30* 163 ± 16 132 ± 16 133 ± 16
CVP (mmHg) Control 5 ± 0 7 ± 1 7 ± 0 6 ± 1 6 ± 1 6 ± 1
AVP 5 ± 1 8 ± 0‡ 8 ± 1 8 ± 1 7 ± 1 8 ± 1
AVP-Dobu 6 ± 1 7 ± 1 9 ± 1 8 ± 1 6 ± 1 6 ± 1
PAOP (mmHg) Control 11 ± 1 12 ± 1 12 ± 1 12 ± 1 12 ± 1 12 ± 1
AVP 9 ± 0 13 ± 1‡ 15 ± 1 15 ± 1 15 ± 1 14 ± 1
AVP-Dobu 11 ± 1 12 ± 2 15 ± 2 15 ± 1 14 ± 1 12 ± 1
SVI (ml beat-1 m-2) Control 69 ± 3 60 ± 3 61 ± 3 62 ± 3 62 ± 3 62 ± 2
AVP 61 ± 3 62 ± 4 48 ± 5 48 ± 6 47 ± 3 47 ± 3
AVP-Dobu 70 ± 3 63 ± 4 49 ± 5 59 ± 6 63 ± 5† 64 ± 5††
LVSWI (g m-1 m2) Control 79 ± 5 57 ± 3‡ 59 ± 3 61 ± 3 64 ± 3 60 ± 2
AVP 75 ± 3 57 ± 4‡ 62 ± 11 62 ± 11 68 ± 12 70 ± 12
AVP-Dobu 76 ± 4 56 ± 5‡‡ 59 ± 6 80 ± 9 95 ± 7**††§ 94 ± 8**†§
RVSWI (g m-1 m2) Control 12 ± 1 15 ± 1 16 ± 1 17 ± 1 17 ± 1 16 ± 1
AVP 12 ± 1 16 ± 1 12 ± 2* 11 ± 1* 13 ± 1 13 ± 1
AVP-Dobu 13 ± 0 15 ± 2 11 ± 2** 14 ± 2 16 ± 2 17 ± 2
AVP, arginine vasopressin; AVP-Dobu, group treated with AVP and dobutamine; MPAP, mean pulmonary arterial pressure; PVRI, pulmonary 
vascular resistance index; CVP, central venous pressure; PAOP, pulmonary artery occlusion pressure; SVI, stroke volume index; LVSWI, left 
ventricular stroke work index; RVSWI, right ventricular stroke work index; T1, healthy baseline; T2, endotoxemic baseline; T3, AVP or placebo; T4, 
T5, T6, AVP + dobutamine 2, 5 and 10 μg kg-1 min-1 or placebo, respectively. *p < 0.05 versus control, **p < 0.01 versus control, †p < 0.05 versus 
AVP, ††p < 0.01 versus AVP, ‡p < 0.05 versus T1, ‡‡p < 0.01 versus T1, ‡‡‡p < 0.001 versus T1, §p < 0.05 versus T4.Available online http://ccforum.com/content/10/5/R144
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decrease in MAP from 100 to about 80 mmHg is a typical fea-
ture of ovine endotoxemia, which represents one of the most
frequently used animal models in investigating vasoactive sub-
stances for the treatment of sepsis. Consequently, studies
using the same or similar sheep models resulted in compara-
ble hemodynamic variables [8,11,14-16,20]. Dose-response
studies in sheep with higher doses of endotoxin did not result
in a MAP of less than 55 mmHg unless the animals died
(Ertmer C, 2006, unpublished observations). In addition, the
marked decrease in SVRI by endotoxin infusion reflects
pronounced vasodilation, similar to what can be observed in
human septic shock [30].
Because we did not investigate regional blood flow and oxy-
gen supply of distinct organs, it can only be speculated that
the AVP-associated decrease in CI was associated with
impaired tissue oxygen supply. However, previous clinical and
experimental studies clearly suggest that an AVP-induced
decrease in CI may contribute to hypoperfusion of splanchnic
organs [9,10,31].
Table 2
Changes in variables of acid-base balance and arterial lactate in endotoxemic sheep.
V a r i a b l e G r o u p T 1 T 2 T 3T 4T 5T 6
Arterial pH Control 7.46 ± 0.00 7.47 ± 0.00 7.46 ± 0.00 7.47 ± 0.00 7.47 ± 0.00 7.47 ± 0.00
AVP 7.45 ± 0.02 7.47 ± 0.02 7.45 ± 0.03 7.46 ± 0.02 7.48 ± 0.02 7.47 ± 0.02
AVP-Dobu 7.45 ± 0.02 7.47 ± 0.01 7.45 ± 0.01 7.45 ± 0.01 7.45 ± 0.01 7.44 ± 0.01
Arterial BE (mmol l-1) Control 4.4 ± 0.5 4.5 ± 0.9 4.9 ± 1 4.6 ± 1 4.1 ± 1 4.2 ± 1
AVP 2.4 ± 1.5 4.0 ± 1.0 3.1 ± 1.4 3.8 ± 1.5 3.1 ± 1.3 3.2 ± 1.3
AVP-Dobu 3.2 ± 0.9 3.2 ± 1 2.3 ± 1 2.1 ± 1.2 1.7 ± 1.2 1.5 ± 1.3
Arterial lactate (mmol l-1) Control 0.7 ± 0.1 1.6 ± 0.2‡‡‡ 1.6 ± 0.1 1.8 ± 0.2 1.9 ± 0.2 2.1 ± 0.2
AVP 0.6 ± 0.1 1.4 ± 0.3‡‡ 1.4 ± 0.3 1.6 ± 0.4 1.6 ± 0.4 1.8 ± 0.4
AVP-Dobu 0.8 ± 0.1 1.5 ± 0.2‡‡‡ 1.7 ± 0.3 1.4 ± 0.2 1.6 ± 0.1 2.0 ± 0.2
VO2I (ml min-1 m-2) Control 332 ± 20 336 ± 20 335 ± 20 336 ± 19 346 ± 17 339 ± 17
AVP 317 ± 12 357 ± 37 287 ± 21 287 ± 21 303 ± 25 307 ± 13
AVP-Dobu 316 ± 16 333 ± 17 265 ± 13 306 ± 17 328 ± 16 361 ± 15
Temperature (°C) Control 39.5 ± 0.1 41.0 ± 0.2‡‡‡ 41.0 ± 0.1 41.0 ± 0.2 41.0 ± 0.2 41.0 ± 0.2
AVP 39.7 ± 0.1 40.7 ± 0.2‡‡‡ 40.7 ± 0.2 40.7 ± 0.2 40.7 ± 0.1 40.7 ± 0.1
AVP-Dobu 39.5 ± 0.1 41.0 ± 0.2‡‡‡ 40.9 ± 0.2 40.9 ± 0.2 40.8 ± 0.1 40.9 ± 0.2
AVP, arginine vasopressin; AVP-Dobu, group treated with AVP and dobutamine; BE, base excess; T1, healthy baseline; T2, endotoxemic baseline; 
T3, AVP or placebo; T4, T5, T6, AVP + dobutamine 2, 5 and 10 μg kg-1 min-1 or placebo, respectively. ‡‡p < 0.01 versus T1, ‡‡‡p < 0.001 versus 
T1.
Table 3
Changes in urinary output and hemoglobin concentration in endotoxemic sheep.
V a r i a b l e G r o u p T 1 T 2T 3T 4 T 5T 6
Urinary output (ml h-1) Control 63 ± 5 94 ± 12 85 ± 13 n/a n/a 97 ± 17
AVP 66 ± 12 108 ± 14 246 ± 41*** n/a n/a 192 ± 22**
AVP-Dobu 69 ± 8 105 ± 14 264 ± 33*** n/a n/a 252 ± 24***
Hemoglobin (g dl-1) Control 10.9 ± 0.3 10.5 ± 0.4 10.4 ± 0.3 10.4 ± 0.4 10.3 ± 0.3 10.2 ± 0.4
AVP 10.5 ± 0.4 10.3 ± 0.3 10.1 ± 0.3 10.2 ± 0.3 10.4 ± 0.4 10.3 ± 0.4
AVP-Dobu 10.5 ± 0.4 10.2 ± 0.3 9.9 ± 0.3 10.1 ± 0.5 10.7 ± 0.5 10.1 ± 0.5
AVP, arginine vasopressin; AVP-Dobu, group treated with AVP and dobutamine; T1, healthy baseline; T2, endotoxemic baseline; T3, AVP or 
placebo; T4, T5, T6, AVP + dobutamine 2, 5 and 10 μg kg-1 min-1 or placebo, respectively. ***p < 0.001 versus control.Critical Care    Vol 10 No 5    Ertmer et al.
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Finally, we emphasize that it was not the aim of the present
study to encourage the use of AVP as a single first-line vaso-
pressor, but to determine the effects of dobutamine infusion
on the AVP-associated decrease in systemic blood flow and
global oxygen transport.
Conclusion
Despite its limitations, this study provides evidence that dob-
utamine is a useful agent for reversing the AVP-associated
depressions in CI and global oxygen supply. Whether a phar-
macological increase in CI and SvO2 improves the overall out-
come in human septic shock treated with vasopressin
analogues should be addressed in randomized controlled clin-
ical trials.
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